NCT06163404View on ClinicalTrials.gov

Open-Label Study to Evaluate the Safety and Effectiveness of the Spirair Implant

NAActive, not recruitingINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

May 31, 2027

Conditions
Nasal Septal DeviationNasal Airway Obstruction
Interventions
DEVICE

Implantation of Spirair Nasal Device using the Spirair delivery system.

The Spirair implant is designed to acutely correct cartilaginous septal deviation and maintain the cartilage in a corrected position for a duration sufficient to allow for cartilaginous remodeling.

Trial Locations (8)

12205

Albany ENT & Allergy Services, PC, Albany

18017

Specialty Physicians, Bethlehem

35242

Alabama Nasal and Sinus Center, Birmingham

40241

Kentuckiana Ear, Nose & Throat, Louisville

70072

Tandem Clinical Research, Marrero

70809

Sinus and Nasal Specialists of LA, Baton Rouge

90503

Breathe Clear Institute, Torrance

98374

Ear Nose Throat & Allergy Associates, Puyallup

All Listed Sponsors
lead

Spirair, Inc

INDUSTRY

NCT06163404 - Open-Label Study to Evaluate the Safety and Effectiveness of the Spirair Implant | Biotech Hunter | Biotech Hunter